Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 9, 2005

View Archived Issues

New mode of cell death achieved with novel CDK4 homologous peptide

Targeting urotensin II for CHF and restenosis following balloon angioplasty

Apoptosis-inducing metal-based complexes described by Irish scientists

Allergy Therapeutics updates status of allergy vaccine programs

Senexis and Galapagos expand collaboration

Idenix outlines plans for valopicitabine phase III trials

Positive results disclosed from MEND-CABG study of MC-1

FDA gives feedback on phase III study protocol for cethromycin in CAP

Cel-Sci signs cooperative agreement with NIAID to test CEL-1000 for bird flu

Study to investigate Phytosel's ability to lower chemotherapy side effects

UGT1A1 test launched to determine appropriate Camptosar dosage

VX-950 enters phase II development for HCV

Neuren raises funding to advance neurological compounds

Merck submits Gardasil BLA

Hylenex receives FDA approval

PXD-101: update on cancer studies

Phenoxodiol effective for malignant SCC of the cervix, vagina or vulva and advanced prostate cancer

Targeting Tie-1 for cancer

A benzodiazepine modulates c-myc

Targeting tissue factor enhances paclitaxel activity

Data on human monoclonal antibodies to TRAIL receptors

Preclinical studies show curcumin prevents breast cancer metastasis

New therapeutics for cancer disclosed in recent patents

Novel agents for alopecia, psoriasis claimed in recent patents

DailyDrugNews.com invites users to participate in Reader Survey

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...